{"id":"NCT02155881","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia","officialTitle":"A Multi-Center, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Phase III (Registration) Study to Assess the Efficacy and Safety of Ciclesonide Nasal Spray (Omnaris®) 200 mcg Once Daily in the Treatment of the Patients With Seasonal Allergic Rhinitis (SAR) in Russia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08","primaryCompletion":"2014-10","completion":"2014-11","firstPosted":"2014-06-04","resultsPosted":"2016-10-06","lastUpdate":"2017-02-02"},"enrollment":80,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Ciclesonide","otherNames":["Omnaris®"]},{"type":"DRUG","name":"Ciclesonide Placebo","otherNames":[]}],"arms":[{"label":"Ciclesonide 200 mcg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to explore the efficacy and safety of Ciclesonide Nasal Spray 200 microgram (mcg) once daily in the treatment of seasonal allergic rhinitis (SAR) in Russian participants.","primaryOutcome":{"measure":"Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Nasal Symptom Scores (TNSS)","timeFrame":"Baseline and Week 1 up to Week 2 (entire treatment period)","effectByArm":[{"arm":"Ciclesonide 200 mcg","deltaMin":7.81,"sd":1.83},{"arm":"Placebo","deltaMin":7.71,"sd":1.63}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9716"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["Headache","Oropharyngeal pain","Cough","Nasal dryness","Insomnia"]}}